§ N° III · Dosage
CJC-1295 Dosage in the Research Literature
The Phase I ladder, the rodent characterization doses, the compounding-pharmacy protocols, and what each register can and cannot tell you.
The published Phase I ladder
CJC-1295 dosage in the published research begins with one trial. Teichman 2006 administered single subcutaneous doses of 30, 60, 125, and 250 µg/kg of CJC-1295 with DAC to healthy adults in a Phase I dose-escalation design [1]. Across the four doses, mean plasma growth-hormone rose 2- to 10-fold in a dose-dependent fashion, and mean plasma IGF-1 rose 1.5- to 3-fold for nine to eleven days [1][2].
No subsequent human trial has expanded the dose range or characterized chronic-dose response in detail. Repeat-dose subgroups in the Teichman protocol — administered every one or two weeks — produced cumulative IGF-1 elevation that remained above baseline for up to twenty-eight days [2]. The Phase I record stops there. There is no Phase II dose-finding study in any indication that has been published in the peer-reviewed literature beyond the halted 2006 ConjuChem HIV-lipodystrophy trial, for which detailed dose information was not made public [13].
Doses used in published research
Doses used in published research
Phase I human trials used 30, 60, 125, and 250 µg/kg single subcutaneous doses (Teichman 2006) [1]. Rodent receptor-characterization studies used low-microgram intravenous or subcutaneous boluses (Jetté 2005) [4]. GHRH-knockout mouse rescue used once-daily subcutaneous DAC variant (Alba 2006) [5]. Compounding-pharmacy protocols cited in the gray literature run 100-300 µg total daily for the no-DAC variant and weekly 1-2 mg for the DAC variant — these are protocol claims, not research-validated regimens [12].
Administration in research settings
Administration in research settings
Subcutaneous injection in all published human trials [1]. Rodent studies used both subcutaneous and intraperitoneal routes; the foundational Jetté 2005 receptor work also used intravenous administration in rats to characterize the albumin-bioconjugate pharmacokinetics directly [4]. The lyophilized peptide is reconstituted with bacteriostatic water in research handling; specific reconstitution volumes depend on vial mass and the intended concentration of the working solution.
Dosing frequency
Dosing frequency
With DAC: weekly in the Phase I trial, supported by the multi-day half-life [1][2]. Without DAC (modified GRF 1-29): gray-literature protocols dose one to three times daily because the half-life is approximately thirty minutes and any sustained GH-axis effect requires repeated stimulation [12]. The biological rhythm reflects the molecule: the DAC variant raises the GH baseline; the no-DAC variant produces brief pulses.
Reconstitution in published protocols
Reconstitution in published protocols
Lyophilized peptide is reconstituted with bacteriostatic water in research settings. Specific volumes depend on the vial mass and intended concentration; this is laboratory handling, not a clinical prescription. The Phase I record (Teichman 2006) does not publish a reconstitution SOP because reconstitution is upstream of trial administration — it is the standard handling of a lyophilized injectable peptide and not part of the dosing endpoint itself [1].
The compounding-pharmacy literature, marked as gray
Compounding-pharmacy dosing protocols for CJC-1295 — typically the no-DAC variant or 'CJC-1295 + ipamorelin' formulations — circulate widely in clinic marketing, compounding-pharmacy product sheets, and direct-to-consumer education. Common citations include 100-300 µg total daily for the no-DAC variant (split into one to three injections) and 1-2 mg weekly for the DAC variant [12].
These are not research-validated regimens. They are protocol claims, generated and circulated within the compounding-pharmacy ecosystem, and not derived from any published trial. The peer-reviewed Phase I doses (30, 60, 125, 250 µg/kg) and the compounding-pharmacy daily-total figures occupy different epistemic registers and should not be conflated. On this page they are rendered in different rules to make the distinction visible at a glance.
What the research-dose record does not say
The published Phase I literature does not say what dose is 'effective' for body composition, anti-aging, sleep, recovery, or any clinical endpoint. It says what dose produces what pharmacodynamic effect on mean plasma GH and IGF-1 in healthy adults [1][2]. Clinical dose-finding belongs to Phase II and III work that has not been completed for CJC-1295.
The pharmacy dossier renders the doses that exist; it does not invent the doses that do not. The reader who wants a clinical dose recommendation will not find one here because none exists in the public record.